Press Releases

You Narrowed By: 2011

Showing 36-70 of 115


2011

September

September 20

Abbott Named Top Dealmaker for Fourth Consecutive Year by The Deal

September 20

Abbott Earns 100 Percent Banned Substance Free Certification for all of its EAS® Sports Nutrition Products

September 15

Abbott Named to Working Mother Magazine’s ‘Best Companies’ List for the Eleventh Consecutive Year

September 15

Abbott Again Recognized as One of the "Top Employers" in the Biotech and Pharmaceutical Industry by Science Magazine

September 15

Abbott Declares 351st Consecutive Quarterly Dividend

September 8

Abbott Initiates International ABSORB BTK Clinical Trial for Treatment of Below-the-Knee Critical Limb Ischemia

September 8

Abbott Named to the Dow Jones Sustainability Indexes for Seventh Consecutive Year in Recognition of Leading Corporate Citizenship Performance
 

August

August 31

Abbott to Present at Morgan Stanley Global Healthcare Conference

August 30

Abbott Introduces New ALK Genetic Test for Specific Form of Non-Small-Cell Lung Cancer

August 30

Abbott Awards CFCareForward Scholarships to 40 Exceptional Graduate and Undergraduate Students Living with Cystic Fibrosis

August 26

Abbott Receives FDA Approval for ALK Gene Test for Lung Cancer Therapy Selection

August 22

Abbott Receives CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery

August 22

FDA Clears Abbott’s Genetic FISH Panel for Leukemia Patient Prognosis

August 16

First Patient in Japan Treated with Abbott's Bioresorbable Vascular Scaffold as Part of Global Clinical Trial

August 16

Abbott Expanding Manufacturing Capacity in China to Meet Demands of Fast-Growing Nutrition Market

August 16

Abbott Receives FDA Approval for Two Three-Month Strengths of Lupron Depot-PED® (leuprolide acetate for depot suspension) for the Treatment of Central Precocious Puberty (CPP)

August 11

Abbott’s PediaSure® Brand Aims to Help Moms With Picky Eaters "Take Back the Table" By Building Lifelong Healthy Eating Habits

August 10

Abbott Introduces Vector-borne Pathogen Test to Detect Microorganisms Carried by Ticks and Other Insects

August 10

Abbott Receives U.S. FDA Approval for RX Herculink Elite® Renal Stent System for Treatment of Renal Artery Disease

August 9

Biogen Idec And Abbott Announce Positive Top-Line Results From The First Registrational Trial For Daclizumab HYP In Relapsing-Remitting Multiple Sclerosis
 

July

July 28

Data Presented at American Association for Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels

July 27

Abbott’s HIV Combo Test Detects Infections Earlier, Provides Valuable Information to Help Prevent Further HIV Transmission and May Save Treatment Costs

July 21

Abbott to Feature Acute HIV Diagnostic, Metabolic Function Tests and Lab Informatics at American Association for Clinical Chemistry Annual Meeting

July 20

Abbott Reports 11 Percent Ongoing Earnings-Per-Share Growth in Second Quarter; Raises 2011 EPS Guidance Range
 

June

June 29

Abbott Hosts Conference Call for Second-Quarter Earnings

June 24

New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients with Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes

June 21

Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune Diseases

June 20

Abbott Receives FDA Approval for a New Six-Month Formulation of Lupron Depot® (leuprolide acetate for depot suspension) for the Palliative Treatment of Advanced Prostate Cancer

June 16

Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type 2 Diabetes

June 14

Abbott Receives FDA Approval For CREON® (Pancrelipase) Infant-Specific Dosage For Patients With Exocrine Pancreatic Insufficiency Due To Cystic Fibrosis

June 13

New National Survey Results Reveal Majority of Men Find it Easier to Care for Their Car Than for Their Personal Health

June 10

Abbott Declares 350th Consecutive Quarterly Dividend

June 9

Abbott Reports Interim Results from Phase III Open-Label Study of Investigational Treatment for Advanced Parkinson's Disease
 

May

May 26

Abbott Statement on Interim Study Results of AIM-HIGH

May 25

Abbott Receives CE Mark for its RealTime Molecular Test for Cytomegalovirus